Ингибиторы фосфоинозитол-3-киназ (PI3K) на основе производных 1,3,5-триазина для таргетной противоопухолевой терапии

Фосфоинозитол-3-киназы (PI3K) могут рассматриваться в качестве мишеней для таргетной терапии злокачественных новообразований. 1,3,5-триазиновый цикл является перспективным скаффолдом при разработке противоопухолевых агентов, действующих на различные биологические мишени опухолевых клеток. В настоящем обзоре рассматриваются производные 1,3,5-триазина (s-триазина) с высокой ингибирующей активностью в отношении PI3K. В том числе обобщены данные по основным структурным фрагментам, играющим ключевую роль в образовании взаимодействий биологически активных соединений с сайтами PI3K. Показана перспективность направления, связанного с разработкой бифункциональных агентов, одновременно воздействующих на две биологические мишени одного или разных сигнальных путей.

1. Zhong L., Li Y., Xiong L. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives // Signal Transduction and Targeted Therapy. – 2021. – Vol. 6, № 1. – P. 201. https://doi.org/10.1038/s41392-021-00572-w.

2. Корман Д. Б. Мишени и механизмы действия противоопухолевых препаратов. – М. : Практическая медицина, 2014. – С. 333.

3. Lee S. Y., Oh S. C. Changing strategies for target therapy in gastric cancer // World Journal of Gastroenterology. – 2016. – Vol. 22, № 3. – P. 1179–1189. https://doi.org/10.3748/WJG.V22.I3.1179.

4. Valerio L., Pieruzzi L., Giani C. et al. Targeted Therapy in Thyroid Cancer: State of the Art // Clinical Oncology. – 2017. – Vol. 29, № 5. – P. 316–324. https://doi.org/10.1016/J.CLON.2017.02.009.

5. Min H. Y., Lee H. Y. Molecular targeted therapy for anticancer treatment // Experimental and Molecular Medicine. – 2022. – Vol. 54. – P. 1670–1694. https://doi.org/10.1038/s12276-022-00864-3.

6. Yu M., Chen J., Xu Z. et al. Development and safety of PI3K inhibitors in cancer // Archives of Toxicology. – 2023. – Vol. 97. – P. 635–650. https://doi.org/10.1007/s00204-02303440-4.

7. Liu P., Cheng H., Roberts T. M., Zhao J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery. – 2009. – Vol. 8. – P. 627–644. https://doi.org/10.1038/nrd2926.

8. Vanhaesebroeck B., Perry M. W. D., Brown J. R. et al. PI3K inhibitors are finally coming of age. Nature Reviews Drug Discovery. – 2021. – Vol. 20. – P. 741–769. https://doi.org/10.1038/s41573-021-00209-1.

9. Occhiuzzi M. A., Lico G., Ioele G. et al. Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents // European Journal of Medicinal Chemistry. – 2023. – Vol. 246. – P. 114971. https://doi.org/10.1016/j.ejmech.2022.114971.

10. Sirico M., D’Angelo A., Gianni C. et al. Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy // Cancers. – 2023. – Vol. 15, № 3. – P. 703. https://doi.org/10.3390/cancers15030703.

11. Mansour M., Lasheen D., Gaber H., Abouzid K. Elaborating piperazinyl-furopyrimidine based scaffolds as phosphoinositol-3-kinase enzyme alpha (PI3Kα) inhibitors to combat pancreatic cancer // RSC Advances. – 2020. – Vol. 10. – P. 32103–32112. https://doi.org/10.1039/D0RA06428A.

12. Naeem M., Iqbal M. O., Khan H. et al. A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer // Molecules. – 2022. – Vol. 27, № 11. – P. 3412. https://doi.org/10.3390/molecules27113412.

13. Xian Q., Zhu D. The Involvement of WDHD1 in the Occurrence of Esophageal Cancer as a Downstream Target of PI3K/AKT Pathway // Journal of Oncology. – 2022. – Vol. 2022. – 871188. https://doi.org//10.1155/2022/5871188.

14. Di Blasio L., Gagliardi P. A., Puliafito A., Primo L. Serine/threonine kinase 3-phosphoinositide-dependent protein kinase-1 (PDK1) as a key regulator of cell migration and cancer dissemination // Cancers. – 2017. – Vol. 9, № 3. – P. 25. https://doi.org/10.3390/cancers9030025.

15. Samuels Y., Wang Z., Bardelli A. et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers // Science. – 2004. – Vol. 304, № 5670. – P. 554. https://doi.org/10.1126/science.1096502.

16. Glaviano A., Foo A., Lam H. et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer // Molecular Cancer. – 2023. – Vol. 22. – P. 138. https://doi.org/10.1186/s12943-023-01827-6.

17. Asati V., Mahapatra D. K., Bharti S. K. PI3K/Akt/ mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives // European Journal of Medicinal Chemistry. – 2016. – Vol. 109. – P. 314–341. https://doi.org/10.1016/j.ejmech.2016.01.012.

18. Ellis H., Ma C. X. PI3K Inhibitors in Breast Cancer Therapy // Current Oncology Reports. – 2019. – Vol. 21. – P. 110. https://doi.org/10.1007/s11912-019-0846-7.

19. Castel P., Toska E., Engelman J. A., Scaltriti M. The present and future of PI3K inhibitors for cancer therapy // Nature Cancer. – 2021. – Vol. 2. – P. 587–597. https://doi.org/10.1038/s43018-021-00218-4.

20. Faes S., Demartines N., Dormond O. Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity // Oxidative Medicine and Cellular Longevity. – 2017. – Vol. 2017. – P. 1726078. https://doi.org/10.1155/2017/1726078.

21. Fan Q. W., Knight Z. A., Goldenberg D. D. et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma // Cancer Cell. – 2006. – Vol. 9, № 5. – P. 341–349. https://doi.org/10.1016/j.ccr.2006.03.029.

22. Wang H. Y., Shen Y., Zhang H. et al. Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor // Future Medicinal Chemistry. – 2018. – Vol. 10, № 20. – P. 2445–2455. https://doi.org/10.4155/fmc-2018-0145.

23. Dai Q., Sun Q., Ouyang X. et al. Antitumor Activity of s-Triazine Derivatives: A Systematic Review // Molecules. – 2023. – Vol. 28, № 11. – P. 4278. https://doi.org/10.3390/molecules28114278.

24. Rathod B., Pawar S., Puri S. et al. Recent Advancements and Developments in the Biological Importance of 1,3,5-Triazines // ChemistrySelect. – 2024. – Vol. 9, № 12. – e202303655. https://doi.org/10.1002/slct.202303655.

25. Dong G., Jiang Y., Zhang F. et al. Recent updates on 1,2,3-, 1,2,4-, and 1,3,5-triazine hybrids (2017–present): The anticancer activity, structure–activity relationships, and mechanisms of action // Archiv der Pharmazie. – 2023. – Vol. 356, № 3. – 2200479. https://doi.org/10.1002/ardp.202200479.

26. Dubey P., Pathak D. P., Ali F. et al. In-vitro Evaluation of Triazine Scaffold for Anticancer Drug Development: A Review // Current Drug Discovery Technologies. – 2023. – Vol. 21, № 2. – 2200479. https://doi.org/10.2174/1570163820666230717161610.

27. Gangasani J. K., Yarasi S., Naidu V. G. M., Vaidya J. R. Triazine based chemical entities for anticancer activity // Physical Sciences Reviews. – 2023. – Vol. 8, № 10. – P. 3545– 3575. https://doi.org/10.1515/psr-2022-0005.

28. Maliszewski D., Drozdowska D. Recent Advances in the Biological Activity of s-Triazine Core Compounds // Pharmaceuticals. – 2022. – Vol. 15, № 2. – P. 221. https://doi.org/10.3390/ph15020221.

29. Singla P., Luxami V., Paul K. Triazine as a promising scaffold for its versatile biological behavior // European Journal of Medicinal Chemistry. – 2015. – Vol. 102. – P. 39–57. https://doi.org/10.1016/j.ejmech.2015.07.037.

30. Liu B. A Systematic Review on Antitumor Agents with 1, 3, 5-triazines // Medicinal Chemistry. – 2015. – Vol. 5, № 3. – P. 131–148. https://doi.org/10.4172/2161-0444.1000255.

31. Lim H. Y., Dolzhenko A. V. 1,3,5-Triazine as a promising scaffold in the development of therapeutic agents against breast cancer // European Journal of Medicinal Chemistry. – 2024. – Vol. 276. – 116680. https://doi.org/10.1016/j.ejmech.2024.116680.

32. Ali M. I., Naseer M. M. Recent biological applications of heterocyclic hybrids containing s-triazine scaffold // RSC Advances. – 2023. – Vol. 13. – P. 30462–30490. https://doi.org/10.1039/d3ra05953g.

33. Karataş Ö., Ceylan Y., Koc Z. 2,4,6-Tris(p-aminoanilino)-1,3,5-triazine: Synthesis and Electron Paramagnetic Resonance (EPR) Analysis // Sakarya University Journal of Science. – 2022. – Vol. 26. – P. 1170–1179. https://doi.org/10.16984/saufenbilder.1135112.

34. Sonawane R. P., Sikervar V., Sasmal S. 1,3,5-Triazines // Comprehensive Heterocyclic Chemistry IV. – 2022. – Vol. 9. – P. 181–283. https://doi.org/10.1016/B9780-12-818655-8.00018-4.

35. Wang Y., Tortorella M. Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review // European Journal of Medicinal Chemistry. – 2022. – Vol. 228. – P. 114039. https://doiorg/10.1016/j.ejmech.2021.114039.

36. Rewcastle G. W., Gamage S. A., Flanagan J. U. et al. Synthesis and biological evaluation of novel analogues of the pan class i phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1 H -benzimidazole (ZSTK474) // Journal of Medicinal Chemistry. – 2011. – Vol. 54, № 20. – P. 7105–7126. https://doi.org/10.1021/jm200688y.

37. Yaguchi S. I., Fukui Y., Koshimizu I. et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor // Journal of the National Cancer Institute. – 2006. – Vol. 98, № 8. – P. 545–556. https://doi.org/10.1093/jnci/djj133.

38. Wang Y., Liu Y., Ge T. et al. Based on 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474), design, synthesis and biological evaluation of novel PI3Kα selective inhibitors // Bioorganic Chemistry. – 2023. – Vol. 130. – P. 106211. https://doi.org/10.1016/j.bioorg.2022.106211.

39. Smith A. L., D’Angelo N. D., Bo Y. Y. et al. Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases // Journal of Medicinal Chemistry. – 2012. – Vol. 55, № 11. – P. 5188–5219. https://doi.org/10.1021/jm300184s.

40. Venkatesan A. M., Dehnhardt C. M., Delos Santos E. et al. Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor // Journal of Medicinal Chemistry. – 2010. – Vol. 53, № 6. – P. 2636–2645. https://doi.org/10.1021/jm901830p.

41. Rossetti S., Broege A., Sen A. et al. Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/ mTOR inhibitors in breast cancer models // NPJ Breast Cancer. – 2024. – Vol. 10, № 1. – P. 40. https://doi.org/10.1038/s41523-024-00648-0.

42. Venkatesan A. M., Chen Z., dos Santos O. et al. PKI179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor // Bioorganic & Medicinal Chemistry Letters. – 2010. – Vol. 20, № 19. – P. 5869–5873. https://doi.org/10.1016/j.bmcl.2010.07.104.

43. Wu T. T., Guo Q. Q., Chen Z. L. et al. Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K/mTOR inhibitors // European Journal of Medicinal Chemistry. – 2020. – Vol. 204. – P. 112637. https://doi.org/10.1016/j.ejmech.2020.112637.

44. Andrs M., Korabecny J., Jun D. et al. Phosphatidylinositol 3-kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKK) inhibitors: Importance of the morpholine ring // Journal of Medicinal Chemistry. – 2015. – Vol. 58, № 1. – P. 41–71. https://doi.org/10.1021/jm501026z.

45. Doogue M. P., Polasek T. M. The ABCD of clinical pharmacokinetics // Therapeutic Advances in Drug Safety. – 2013. – Vol. 4, № 1. – P. 5–7. https://doi.org/10.1177/2042098612469335.

46. Dugar S., Hollinger F. P., Mahajan D. et al. Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines // ACS Medicinal Chemistry Letters. – 2015. – Vol. 6, № 12. – P. 1190–1194. https://doi.org/10.1021/acsmedchemlett.5b00322.

47. Collins G. P., Eyre T. A., Schmitz-Rohmer D. et al. A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma // HemaSphere. – 2021. – Vol. 5, № 11. – P. e656. https://doi.org/10.1097/HS9.0000000000000656.

48. Yang K., Tang X., Xu F. et al. PI3K/mTORC1/2 inhibitor PQR309 inhibits proliferation and induces apoptosis in human glioblastoma cells // Oncology Reports. – 2020. – Vol. 43, № 3. – 773–782. https://doi.org/10.3892/or.2020.7472.

49. Rozengurt E., Soares H. P., Sinnet-Smith J. Suppression of feedback loops mediated by pi3k/mtor induces multiple overactivation of compensatory pathways: An unintended consequence leading to drug resistance // Molecular Cancer Therapeutics. – 2014. – Vol. 13, № 11. – P. 2477–2488. https://doi.org/10.1158/1535-7163.MCT-14-0330.

50. Gremke N., Besong I., Stroh A. et al. Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs // Signal Transduction and Targeted Therapy. – 2025. – Vol. 10, № 1. – P. 92. https://doi.org/10.1038/s41392-025-02180-4.

51. Zhang B., Zhang Q., Xiao Z. et al. Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors // Bioorganic Chemistry. – 2020. – Vol. 95. – 103525. https://doi.org/10.1016/j.bioorg.2019.103525.

52. Wellbrock C., Karasarides M., Marais R. The RAF proteins take centre stage // Nature Reviews Molecular Cell Biology. – 2004. – Vol. 5. – P. 875–885. https://doi.org/10.1038/nrm1498.

53. Davies H., Bignell G. R., Cox C. et al. Mutations of the BRAF gene in human cancer // Nature. – 2002. – Vol. 417. – P. 949–954. https://doi.org/10.1038/nature00766.